7 King-Sized Yields (up to 12.4%) That Wall Street Can’t Stand

Our Archive

Search completed

When the Wall Street cheerleaders actually dislike a stock—well, that sure commands our contrarian attention.

Today we’ll cover one of my favorite traditions, which is fading the opinions of analysts. You know, the guys who typically slap a Buy rating on everything they see?

It sounds counterintuitive, but we don’t want Buy ratings on our stocks. Give us Holds and Sells and general apathy. Or, even better, disgust.

When every analyst rates a stock a Buy, it feels “safe” to purchase. But really, it’s anything but. With nobody left to upgrade, there is nothing to do but wait for the dreaded downgrade.… Read more

Read More

I was talking with an old college buddy the other day, and he was lamenting his recent investment performance. Up until a few years ago, he could do no wrong chasing the latest hot trade in small-cap biotech stocks.

We’re not talking beer money winnings, either. We’re talking life-changing money. My friend’s best trade to date was buying 5,000 shares of Pacific Biosciences (PACB) in the early days of the pandemic at $3.50 a share …. then selling half of it at around $35 a share last year!

That’s $70,000 in profits in less than two years.

On one trade.

Of course, things have been much harder for him in 2022.… Read more

Read More

Categories